All In Biotech

Drug Trial Radar · NCT06094283

First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

Double-blind, Placebo Controlled, First in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of YCT-529

Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Dec 20, 2023

Primary completion

Jun 18, 2024

Study completion Jun 18, 2024

Sponsor

Lead sponsor
YourChoice Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 25 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subjects.

Conditions

  • Male Contraception

Interventions

  • YCT-529Drug

    Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg

  • YCT-529 PlaceboDrug

    YCT-529 Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and nature of any adverse events, dose-limiting adverse events and serious adverse adverse events.Time frame: Baseline to 43 days for subjects participating in Cohorts 1 and 2 participating in the 2 periods; Baseline to 10 weeks for Cohorts 1 and 2 that also complete the fed portion of the study; and Baseline to 16 weeks if waiting for other cohorts to finish
  2. Vital signs assessment (heart rate)Time frame: Baseline to Day 15
  3. Vital signs assessment (blood pressure)Time frame: Baseline to Day 15
  4. Vital signs assessment (oral temperature)Time frame: Baseline to Day 15
  5. 12-lead ECG assessment (heart rate)Time frame: Baseline to Day 15
  6. 12-lead ECG assessment (QT interval)Time frame: Baseline to Day 15
  7. 12-lead ECG assessment (QTcF Interval)Time frame: Baseline to Day 15
  8. 12-lead ECG assessment (PR Interval)Time frame: Baseline to Day 15
  9. 12-lead ECG assessment (QRS Duration)Time frame: Baseline to Day 15
  10. Clinical laboratory assessments (hematology blood sample tests)Time frame: Baseline to Day 15
  11. Clinical laboratory assessments (coagulation blood sample tests)Time frame: Baseline to Day 15
  12. Clinical laboratory assessments (clinical chemistry blood sample tests)Time frame: Baseline to Day 15
  13. Clinical laboratory assessments (urine sample tests)Time frame: Baseline to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Nottingham, East Midlands, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.